Christoph Rader, Ph.D.
Affiliations: | 2012 | Scripps Research Institute | |
2003-2012 | Experimental Transplantation and Immunology Branch | NCI, Somers, CT, United States |
Google:
"Christoph Rader"Mean distance: 16.43 (cluster 11) | S | N | B | C | P |
Cross-listing: Chemistry Tree
Parents
Sign in to add mentorPeter Sonderegger | grad student | 1991-1995 | Universität Zürich |
Carlos F. Barbas, III | post-doc | 1996-1999 | Scripps Institute (Chemistry Tree) |
BETA: Related publications
See more...
Publications
You can help our author matching system! If you notice any publications incorrectly attributed to this author, please sign in and mark matches as correct or incorrect. |
Stepanov AV, Xie J, Zhu Q, et al. (2023) Control of the antitumour activity and specificity of CAR T cells via organic adapters covalently tethering the CAR to tumour cells. Nature Biomedical Engineering |
Chang J, Rader C, Peng H. (2023) A mammalian cell display platform based on scFab transposition. Antibody Therapeutics. 6: 157-169 |
Cyr MG, Wilson HD, Spierling AL, et al. (2023) Concerted antibody and antigen discovery by differential whole-cell phage display selections and multi-omic target deconvolution. Journal of Molecular Biology. 168085 |
Steele AD, Kiefer AF, Hwang D, et al. (2023) Application of a Biocatalytic Strategy for the Preparation of Tiancimycin-Based Antibody-Drug Conjugates Revealing Key Insights into Structure-Activity Relationships. Journal of Medicinal Chemistry |
Cyr MG, Mhibik M, Qi J, et al. (2022) Patient-derived Siglec-6-targeting antibodies engineered for T-cell recruitment have potential therapeutic utility in chronic lymphocytic leukemia. Journal For Immunotherapy of Cancer. 10 |
Hwang D, Nilchan N, Park H, et al. (2022) Sculpting a Uniquely Reactive Cysteine Residue for Site-Specific Antibody Conjugation. Bioconjugate Chemistry |
Hu EY, Do P, Goswami S, et al. (2021) The ROR1 antibody-drug conjugate huXBR1-402-G5-PNU effectively targets ROR1+ leukemia. Blood Advances. 5: 3152-3162 |
Lin CW, Zheng T, Grande G, et al. (2021) A new immunochemical strategy for triple-negative breast cancer therapy. Scientific Reports. 11: 14875 |
Goydel RS, Rader C. (2021) Antibody-based cancer therapy. Oncogene. 40: 3655-3664 |
Nilchan N, Alburger JM, Roush WR, et al. (2021) An Engineered Arginine Residue of Unusual pH-Sensitive Reactivity Facilitates Site-Selective Antibody Conjugation. Biochemistry |